TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9527417

Group type: COMPARATOR
Intervention: Placebo (distilled water, n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Antiseptic product (mixture of chlorexidine, benzalkonium chloride and benzylic alcohol, n = 16)
Number of subjects: 32
Study: 7523562

Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) 40 micrograms/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 2895786

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30486682

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day carvacrol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day carvacrol
Number of subjects: 2
Study: 30979653

Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 58

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 58
Study: 28000167

Group type: EXPERIMENTAL
Intervention: apixaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 0
Study: 26100954

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof SA60AT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOL (BL27)
Number of subjects: 120
Study: 23787501

Group type: COMPARATOR
Intervention: Alpha-lipoic acid (600 mg per day for 14 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (for 2 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 50
Study: 21666557

Group type: EXPERIMENTAL
Intervention: LigaSure™ hemorrhoidectomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 52
Study: 18682969

Group type: EXPERIMENTAL
Intervention: Timolol-Dorzolamide drops twice daily (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No eyedrops (control; n = 19)
Number of subjects: 38
Study: 17052779

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 0.4 mg daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 1.0 mg daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 5.0 mg daily
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (pooled subjects with baseline NT‐proBNP > 40 ng/L)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 15747313

Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 11

Group type: COMPARATOR
Intervention: HDF
Number of subjects: 11
Study: 11552016

Group type: EXPERIMENTAL
Intervention: APOE epsilon4 allele carriers (n = 85)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Long-term immunotherapy in epsilon4 carriers
Number of subjects: 374
Study: 9722293

Group type: EXPERIMENTAL
Intervention: CT+G‐CSF
Number of subjects: 105

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 105
Study: 7928875

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: First exercise bout
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Second exercise bout
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Third exercise bout
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heavy ergometer exercise
Number of subjects: 10
Study: 2835976

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29224843

Group type: EXPERIMENTAL
Intervention: Intensified preoperative education
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (standard preoperative education)
Number of subjects: 62
Study: 26919801

Group type: EXPERIMENTAL
Intervention: Colchicine (mean prescribed dose 2.8 mg within the first 24 hours, cumulative dose 6.9 mg over three days)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 349
Study: 25689513

Group type: EXPERIMENTAL
Intervention: Zn-containing toothpaste/rinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sr-containing toothpaste/rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zn-containing rinse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tooth- and tongue brushing with Sr- and Zn-containing toothpastes
Number of subjects: 30
Study: 26527931

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 110 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) and Fluticasone furoate (FF)
Number of subjects: 24
Study: 21434379

Group type: EXPERIMENTAL
Intervention: Geviskon forte (10 ml, 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aluminum-magnesium antacid (1 sachet, 3 times a day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Geviskon
Number of subjects: 60
Study: 18058086

Group type: EXPERIMENTAL
Intervention: Ligament balancing with an instrumented joint spreader device
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ligament balancing using fixed thickness spacer blocks
Number of subjects: 16
Study: 17162171

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 381

Group type: COMPARATOR
Intervention: Reduction with internal fixation
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 381
Study: 12914399

Group type: EXPERIMENTAL
Intervention: Combination therapy (iodide 150 microgram + Levothyroxine 75 microgram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (150 microgram iodide + 75 microgram L-thyroxine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levothyroxine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodide or combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups with adequate controls and adjustment of Levothyroxine dosage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with Levothyroxine and iodide
Number of subjects: 0
Study: 10707032

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 9018517

Group type: EXPERIMENTAL
Intervention: Glucose (trial G)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucose plus branched-chain amino acids (BCAA: trial B)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (trial P)
Number of subjects: 9
Study: 1527319

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (164 micrograms, twice a day for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4076119

Group type: EXPERIMENTAL
Intervention: High-intensity exercise group (80% maximum heart rate)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group (55% maximum heart rate)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 33
Study: 30361960

Group type: EXPERIMENTAL
Intervention: Sprout soybean milk (SS)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Soybean milk (S)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Rice milk (C)
Number of subjects: 288
Study: 28870836

Group type: EXPERIMENTAL
Intervention: Community-based group exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Medical care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clinic-based manual therapy and individual exercise
Number of subjects: 50
Study: 27504562

Group type: EXPERIMENTAL
Intervention: Ganglioside GM1
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (antiviral, analgesic, and neurotrophic agents)
Number of subjects: 140
Study: 25110443

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppository)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study: 22679142

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Coumarin treatment
Number of subjects: 1362
Study: 20926006

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegic infusion via the aortic root and additional cardioplegia via vein or free arterial grafts (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antegrade cardioplegic infusion only via the aortic root (group A)
Number of subjects: 0
Study: 18828743

Group type: EXPERIMENTAL
Intervention: Measles vaccination (MV) at 6 and 9 months
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Measles vaccination (MV) at 9 months only
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 2200
Study: 16096169

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC) vs 1.5 mg estradiol (E(2))
Number of subjects: 176
Study: 12814152

Group type: EXPERIMENTAL
Intervention: Salmeterol MDI (50 microg b.d.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10968237

Group type: EXPERIMENTAL
Intervention: Irbesartan (3.3 mg/kg body weight daily)
Number of subjects: 20
Study: 8792730

Group type: EXPERIMENTAL
Intervention: Predonation of 2 autologous units of blood before THR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving homologous blood transfusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (predonation and control)
Number of subjects: 80
Study: 1637513

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional antihypertensive treatment
Number of subjects: 70
Study: 6383009

Group type: EXPERIMENTAL
Intervention: Protein at a level of 1.5 g/kg desirable weight per day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Identical diet with half the protein replaced by carbohydrate
Number of subjects: 6
Study: 29713890

Group type: EXPERIMENTAL
Intervention: Hemostatic collagen sponge with cyanoacrylate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hemostatic collagen sponge
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Graft width < 14 mm
Number of subjects: 44
Study: 29672821

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day, up-titrated to 80 mg after 6 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg/day, up-titrated to 40 mg after 6 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 78
Study: 27109860

Group type: EXPERIMENTAL
Intervention: 450 mg purified 5‐CGA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 900 mg purified 5‐CGA
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 mg purified 5‐CGA (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg purified (‐)‐epicatechin (positive control)
Number of subjects: 16
Study: 24581245

Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 262
Study: 23273022

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed net (LLIN)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT) for uncomplicated malaria
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed net (LLIN) and ACT
Number of subjects: 100
Study: 20959430

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (30g infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 20
Study: 17600452

Group type: EXPERIMENTAL
Intervention: GTH-Only
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: GTH-Plus
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1071
Study: 16259308

Group type: EXPERIMENTAL
Intervention: Active laser acupuncture (0.5J delivered to six to eight acupuncture sites, twice weekly for four weeks then weekly for a further four weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control (inactive laser treatment)
Number of subjects: 30
Study: 11570619

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9762021

Group type: EXPERIMENTAL
Intervention: 0.005% calcipotriol ointment twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment once daily
Number of subjects: 0
Study: 7801756

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament injury group (n=20)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Notch width ≤ 17 mm
Number of subjects: 46
Study: 3432357

Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP) 2 g
Number of subjects: 39

Group type: COMPARATOR
Intervention: Very low dose of L-tryptophan (0.04 g)
Number of subjects: 39
Study: 30541645

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-RRT
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Early RRT (initial RRT on KDIGO stage‐2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Delayed RRT (including self-improvement without RRT on KDIGO stage‐2 and initial RRT on KDIGO stage‐3)
Number of subjects: 132
Study: 28199143

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 246

Group type: COMPARATOR
Intervention: R-HDS
Number of subjects: 246
Study: 23439365

Group type: EXPERIMENTAL
Intervention: IDX184 50 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IDX184 50 mg twice daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IDX184 100 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IDX184 150 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IDX184 100 mg twice daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IDX184 200 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81

Group type: COMPARATOR
Intervention: pegylated interferon-α2a and ribavirin alone
Number of subjects: 81
Study: 22080004

Group type: EXPERIMENTAL
Intervention: 6.25% glucose and 18.75% dextrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.25% sucrose and 18.75% dextrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.25% maltose and 18.75% dextrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% dextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.4 mL diluent-injected control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninjected control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All carbohydrate treatments except glucose and dextrin combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All carbohydrates except for 25% dextrin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E19 to the day of hatch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day of hatch
Number of subjects: 0
Study: 17662284

Group type: EXPERIMENTAL
Intervention: Laser thinning of the zona pellucida (ZP) using a 1,480-nm noncontact laser
Number of subjects: 180

Group type: COMPARATOR
Intervention: Laser breaching of the zona pellucida (ZP) creating a hole about 30 microm in size
Number of subjects: 180
Study: 17228991

Group type: EXPERIMENTAL
Intervention: Placebo treatment (decaffeinated coffee)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeinated orange juice (true information)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine (both treatments)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine (correctly informed participants)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no caffeine or placebo)
Number of subjects: 90
Study: 12577196

Group type: EXPERIMENTAL
Intervention: Local DEXA analysis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Central DEXA analysis
Number of subjects: 80
Study: 10666539

Group type: EXPERIMENTAL
Intervention: granisetron+5-HT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: propranolol+5-HT
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5-HT
Number of subjects: 24

Group type: COMPARATOR
Intervention: saline+5-HT
Number of subjects: 24
Study: 9004051

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 24
Study: 8403960

Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methohexital (5 mg/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/mL)
Number of subjects: 30
Study: 6406471

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31520611

Group type: EXPERIMENTAL
Intervention: Anodal tDCS during surgical skill training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS during surgical skill training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Anodal tDCS paired with surgical training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgical training without tDCS
Number of subjects: 22
Study: 29618772

Group type: EXPERIMENTAL
Intervention: Phosphorous application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drought stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Well-watered plants
Number of subjects: 0
Study: 27045953

Group type: EXPERIMENTAL
Intervention: Engage in Education‐London (EiE‐L) intervention
Number of subjects: 742

Group type: COMPARATOR
Intervention: Employability seminar (control)
Number of subjects: 742
Study: 25193590

Group type: EXPERIMENTAL
Intervention: Honey, antibiotic, and acetaminophen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antibiotic and acetaminophen
Number of subjects: 80
Study: 22006408

Group type: EXPERIMENTAL
Intervention: Tegobuvir 40 mg BID + GS-9256 75 mg BID
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tegobuvir 40 mg BID + GS-9256 75 mg BID + RBV 1,000-1,200 mg daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tegobuvir 40 mg BID + GS-9256 75 mg BID + Peg-IFN alpha-2a (180 μg once-weekly) + RBV
Number of subjects: 46

Group type: COMPARATOR
Intervention: All groups received Peg-IFN/RBV after 28 days
Number of subjects: 46
Study: 19556519

Group type: EXPERIMENTAL
Intervention: Patsari stove
Number of subjects: 552

Group type: COMPARATOR
Intervention: Open fire
Number of subjects: 552
Study: 17526634

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study: 16781159

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 66
Study: 15061623

Group type: EXPERIMENTAL
Intervention: Vaccination against influenza
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 301
Study: 10673254

Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.5 mg/kg infused intravenously for 3 minutes immediately before reperfusion during primary PTCA.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.5 mg/kg infused intravenously while continuous ECG recordings were obtained.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nondipyridamole (non-DP) group.
Number of subjects: 61
Study: 9139621

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) apheresis for 59 months (Liposorber system, Kaneka, Japan) and 19 months (immunoadsorption system, special Lp(a) columns; Lipopak; Pocard, Russia)
Number of subjects: 2
Study: 1848567

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.9% saline rinse
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1% SLS rinse
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2% triclosan rinse
Number of subjects: 16
Study: 6340825

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy with BCG-CWS
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study: 31944339

Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 149
Study: 31154599

Group type: EXPERIMENTAL
Intervention: PBM + immediate loading (IL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PBM + delayed loading (DL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: IL only
Number of subjects: 19

Group type: COMPARATOR
Intervention: DL only
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 19
Study: 28559516

Group type: EXPERIMENTAL
Intervention: ATT with cholecalciferol
Number of subjects: 300

Group type: COMPARATOR
Intervention: ATT
Number of subjects: 300
Study: 26659931

Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment 2% applied twice daily (BID)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment 0.5% or 2% applied once daily (QD)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment 0.5% or 2% applied twice daily (BID)
Number of subjects: 86